SNOA - Sonoma Pharma rises 22% on UTI product launch in New Zealand Australia and South Africa

Sonoma Pharma (NASDAQ:SNOA) is trading ~22% higher after it launched its urinary tract infection catheter and bladder rinse product in New Zealand, Australia and South Africa. The product, Microdox, is a non-irritating and non-toxic solution and is for the treatment and prevention of infections in the urinary tract and bladder. The company said Microdox is currently available through its partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa. In January, the company shares rose after the firm said it added Salus Medical as a distribution partner in the U.S. for dental care. As of Tuesday's close, SNOA had fallen ~51% in the last 12 months.

For further details see:

Sonoma Pharma rises 22% on UTI product launch in New Zealand, Australia and South Africa